Esophageal lymphoma is one of the rarest localizations of gastrointestinal lymphoma — constituting 1-2% of all GI lymphomas. Primary esophageal lymphoma is extremely rare; most cases represent secondary involvement from adjacent mediastinal or gastric lymphoma. The most common non-Hodgkin lymphoma (NHL) subtype is diffuse large B-cell lymphoma (DLBCL). Primary lymphoma is rare in the esophagus because lymphoid tissue (MALT) is limited — stomach and small bowel have much more Peyer patches and MALT tissue. On imaging, it presents as diffuse wall thickening or polypoid mass, typically enhances homogeneously, and may show long segment involvement without causing significant obstruction. Incidence is increased in HIV/AIDS-related immunosuppression. Dramatic response to treatment is characteristic.
Age Range
40-80
Peak Age
60
Gender
Male predominant
Prevalence
Rare
Lymphomas arise from clonal proliferation of lymphoid cells. MALT (mucosa-associated lymphoid tissue) is extremely limited in the esophagus; therefore primary esophageal lymphoma is the rarest GI lymphoma localization — secondary involvement is much more common, with mediastinal lymphadenopathy or gastric lymphoma spreading to the esophagus by direct invasion. In DLBCL, rapidly proliferating B-lymphocytes infiltrate the submucosal layer causing wall thickening — but this infiltration generally relatively preserves muscularis propria, so obstruction develops later compared to carcinomas and the lumen may even remain dilated (aneurysmal dilatation). Lymphoma cells infiltrating the autonomic nerve plexus disrupt peristaltic activity — this mechanism is the fundamental cause of lumen preservation. Homogeneous enhancement reflects the tumor's diffuse cellular infiltration and homogeneous vascularity — necrosis is rare compared to carcinomas because lymphoma cells are less dependent on irregular neovascularity. Marked diffusion restriction on DWI results from lymphoma cells' high nucleus-to-cytoplasm ratio and high cellularity — ADC values are significantly lower than carcinomas.
Relative preservation or expansion of the lumen despite marked wall thickening. Lymphoma infiltrates the autonomic nerve plexus of muscularis propria disrupting peristaltic activity — the lumen may remain dilated rather than showing stenosis as seen in carcinomas. This finding is quite specific to lymphoma and is an important clue for differentiating from carcinoma/GIST.
Diffuse concentric wall thickening (usually >1.5 cm, may be >20 mm) with homogeneous enhancement in the esophageal wall on CT. Wall thickening may extend over a long segment (>5 cm) and luminal narrowing is less prominent compared to carcinoma — may even show aneurysmal dilatation. Peritumoral fat planes are generally preserved. Necrosis and cavitation are rare. Enhancement in portal venous phase is moderate and homogeneous.
Report Sentence
Diffuse concentric wall thickening measuring approximately ___ cm in length with homogeneous enhancement in the esophageal wall, with relative luminal preservation; lymphoma should be the primary consideration.
Marked diffusion restriction on DWI with very low signal on ADC map (ADC values generally <0.8 × 10⁻³ mm²/s). Lymphoma's high cellularity and high nucleus-to-cytoplasm ratio markedly restrict water diffusion. This finding is characterized by lower ADC values than both SCC and adenocarcinoma — an important clue in differential diagnosis of lymphoma. Post-treatment increase in ADC values is an early indicator of response.
Report Sentence
Marked diffusion restriction on DWI with very low signal on ADC map (ADC: ___ × 10⁻³ mm²/s) in esophageal wall thickening, consistent with high cellularity; lymphoma should be considered.
Very prominent FDG uptake is observed in esophageal lymphomas on PET-CT (SUVmax generally >10, may be >15 in DLBCL). FDG-PET is the gold standard for lymphoma staging — Lugano classification uses PET-based staging. Accompanying nodal and extranodal involvement is detected. Post-treatment interim PET (after 2-3 cycles) is critical for early response assessment — Deauville scoring is used (1-5 scale, 1-3 considered negative).
Report Sentence
Very prominent FDG uptake with SUVmax ___ in esophageal wall thickening consistent with lymphoma; whole-body PET-CT evaluation recommended for Lugano staging.
Intermediate-to-high homogeneous signal in esophageal wall thickening on T2-weighted sequence. Signal level higher than muscle, lower than fluid. T2 signal intensity varies by lymphoma subtype — DLBCL generally shows higher T2 signal than MALT lymphoma. Homogeneous signal reflects lymphoma's uniform cellular infiltration — heterogeneity from necrosis/fibrosis seen in carcinomas is absent.
Report Sentence
Homogeneous intermediate-to-high signal on T2 in esophageal wall thickening, consistent with lymphomatous infiltration.
In some cases, lymphoma may present as polypoid intraluminal mass rather than diffuse wall thickening. The mass is broad-based, homogeneously enhancing, and usually smooth-surfaced with rare ulceration. Polypoid form is more commonly seen in MALT lymphoma and mantle cell lymphoma (lymphomatous polyposis). Mass is usually located in mid-to-lower esophagus. Luminal obstruction may be more prominent in polypoid form.
Report Sentence
Broad-based, homogeneously enhancing polypoid mass with smooth surface in the esophageal lumen; consistent with lymphoma.
Mediastinal lymphadenopathy accompanying esophageal lymphoma — particularly common in secondary involvement. Lymph nodes enhance homogeneously, may be conglomerate, and central necrosis is generally not seen (different from Hodgkin lymphoma). Subcarinal, para-aortic, paraesophageal, and cervical stations should be evaluated. Large mediastinal mass (bulky disease, >7.5 cm) has prognostic significance and may change treatment strategy.
Report Sentence
Multiple mediastinal lymphadenopathy accompanying esophageal wall thickening, largest measuring ___ mm in short axis; consistent with nodal involvement in the context of lymphoma.
Criteria
Most common esophageal lymphoma subtype (60-70%). Diffuse infiltration of large B-lymphocytes. Aggressive biology, rapid growth. CD20 positive.
Distinct Features
Marked diffuse wall thickening on CT, very high FDG uptake (SUVmax >15), very low ADC on DWI (<0.7). R-CHOP chemoimmunotherapy is standard treatment. Rare as primary esophageal — usually secondary spread.
Criteria
Indolent B-cell lymphoma. Originating from mucosa-associated lymphoid tissue. Associated with chronic inflammation.
Distinct Features
Focal polypoid mass or limited wall thickening on CT. FDG uptake lower than DLBCL. Slow course, localized. Radiation therapy or chlorambucil may suffice. Very rare in esophagus.
Criteria
Aggressive B-cell lymphoma. t(11;14), cyclin D1 overexpression. Multiple polyposis in GI.
Distinct Features
Multiple polypoid lesions throughout GI tract on CT. High FDG uptake. Requires intensive chemoimmunotherapy. Prognosis worse than DLBCL. Rare in esophagus, common in colon/small bowel.
Distinguishing Feature
SCC shows mucosal destruction, irregular borders, and prominent luminal narrowing; lymphoma shows submucosal infiltration, smooth borders, and relative lumen preservation. SCC enhances heterogeneously with common necrosis; lymphoma enhances homogeneously with rare necrosis. SCC has regional LAP while lymphoma shows widespread nodal involvement.
Distinguishing Feature
GIST presents as focal submucosal mass; lymphoma shows diffuse concentric wall thickening. On EUS, GIST originates from 4th layer while lymphoma originates from layers 2-3. GIST is c-KIT positive, lymphoma is CD20 positive. GIST may be heterogeneous, lymphoma is homogeneous.
Distinguishing Feature
Adenocarcinoma develops on Barrett background in distal esophagus/GEJ; lymphoma can occur in any segment. Adenocarcinoma is eccentric with prominent obstruction; lymphoma is concentric with preserved lumen. ADC values of lymphoma on DWI are lower than adenocarcinoma.
Distinguishing Feature
Metastasis has known primary tumor history and usually focal mass; lymphoma shows diffuse thickening and very high FDG. Metastasis seen in multiple organs while lymphoma shows lymphatic distribution. ADC in lymphoma on DWI is lower than metastasis.
Urgency
urgentManagement
medicalBiopsy
NeededFollow-up
specialist-referralDeep endoscopic biopsy or EUS-guided biopsy is essential for diagnosis — superficial biopsies may be insufficient due to submucosal lesion. Subtype is determined by immunohistochemistry (CD20, CD3, Ki-67). Staging is performed with PET-CT using Lugano classification. DLBCL treatment is R-CHOP chemoimmunotherapy, radiation therapy or chlorambucil may suffice for MALT lymphoma. Treatment response is assessed using Deauville scoring on interim PET-CT. Surgery is not required — chemotherapy is primary treatment. Dramatic response to treatment is characteristic.
Treatment of esophageal lymphoma is chemotherapy + radiation (surgery usually not needed). DLBCL is the most common subtype in primary lymphoma. Treatment response is good and prognosis depends on stage. PET-CT is used for staging and response assessment.